ARS Pharmaceuticals (SPRY) Interest Expenses (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Interest Expenses of $35.6 million for Q1 2026, up 1527.69% sequentially from $2.2 million in Q4 2025, and up 323218.18% YoY from N/an in Q1 2025.
ARS Pharmaceuticals (SPRY) Interest Expenses (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Interest Expenses for 7 years, with the latest figure at $35.6 million in Q1 2026.
- Quarterly Interest Expenses rose 323218.18% year-over-year to $35.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.6 million (up 323218.18% YoY) and the FY2025 annual result came in at $78.2 million, up 9.32% from the prior year.
- Interest Expenses advanced to $35.6 million in Q1 2026 per SPRY's latest filing, from $2.2 million in the prior quarter.
- Over five years, Interest Expenses peaked at $39.4 billion in Q1 2023 and troughed at -$184000.0 in Q4 2024.
- A 5-year average of $5.8 billion and a median of $43.8 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses surged 875193.2% in 2023, then slumped 99.99% in 2025.
- Over 5 years, Interest Expenses stood at $100000.0 in 2022, then surged by 15442325.0% to $15.4 billion in 2023, then sank by 100.0% to -$184000.0 in 2024, then jumped by 1287.5% to $2.2 million in 2025, then jumped by 1527.69% to $35.6 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $35.6 million, $2.2 million, and $59.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 35.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.17 Mn |
| Jun 30, 2026 | 35.17 Mn |
| Mar 31, 2026 | 35.57 Mn |
| Mar 31, 2026 | 35.57 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Sep 30, 2025 | 59.82 Mn |
| Sep 30, 2025 | 59.82 Mn |
| Jun 30, 2025 | 174.54 Mn |
| Jun 30, 2025 | 174.54 Mn |
| Mar 31, 2025 | 11,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Dec 31, 2024 | -184,000.00 |
| Dec 31, 2024 | -184,000.00 |
| Sep 30, 2024 | 134.14 Mn |
| Sep 30, 2024 | 134.14 Mn |
| Jun 30, 2024 | 52.05 Mn |
| Jun 30, 2024 | 52.05 Mn |
| Mar 31, 2024 | 77.54 Mn |
| Mar 31, 2024 | 77.54 Mn |